

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<b>Applicant:</b>	Paul J. Coleman	<b>Art Unit:</b>	To be determined
<b>Attorney Docket No.</b>	21442P	<b>Examiner:</b>	To be determined
<b>PCT Appl. No.:</b>	PCT/US04/025856 Filed: 09 August 2004		
<b>Filing Date:</b>	February 7, 2006		
<b>For:</b>	MITOTIC KINESIN INHIBITORS		

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**LETTER**

Sir:

In compliance with 37 C.F.R. 1.821(f) of the Rules of Practice In Patent Cases: Application Disclosures Containing Nucleotide And/Or Amino Acid Sequences, the signature page and following statement are being submitted herewith.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

The enclosed diskette contains the Sequence Listing for case number  
21442P.

Respectfully submitted,

By:

  
\_\_\_\_\_  
David A. Muthard  
Registration No. 35,297  
Attorney for Applicants

Merck & Co., Inc.  
P.O. Box 2000 – RY 60-30  
Rahway, New Jersey 07065-0907  
Telephone No. (732) 594-3903

Date: February 7, 2006